Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Minot Light Capital Partners Tom Wetherald and Eddie Reilly | “Outset Medical (OM) was by far the biggest loser for the quarter, as the company missed earnings and experienced a massive sell-off. We believe the decline was compounded by significant tax-loss selling by large institutions that became price insensitive toward year-end. OM closed 2025 at $3.71 per share and bottomed around $3.30 despite having $4.55 of net cash per share and net current asset value of $7.11 per share. We feel the company is on track to do about $125M in sales, with a meaningful portion consisting of high-margin recurring revenue. For these reasons, we substantially increased our position, making OM the largest position in the fund. BSD Analysis: Outset Medical is attempting to disrupt dialysis delivery with home and acute-care solutions. Clinical benefits exist, but adoption has been slower than early optimism suggested. Regulatory, reimbursement, and hospital economics drive uptake. Cash burn remains the central risk. Investors punish the stock accordingly. If utilization scales, operating leverage is dramatic. Dialysis demand is not discretionary. Execution, not science, is the hurdle now. This is medtech asymmetry at work.” | BULL | Q4 2025 Jan 15, 2026 | View Pitch |
Minot Light Capital Partners Tom Wetherald and Eddie Reilly | “Outset Medical is a company that we made a large position when it fell below $1.00/share due to dilution from a very constructive financing with several high-quality healthcare investors, which essentially prevented a liquidity crisis for the company. Outset provides dialysis equipment and consumables for healthcare facilities and the home. We believe the company is reasonably well positioned with a recurring revenue model and good growth prospects. Our ability to purchase the stock at highly attractive valuations was due to several technical inefficiencies endemic to the micro-cap cap market, which is what we love about the space. The choppy trading of shares after the stock fell below $1.00 cumulated when they announced a reverse stock split via a press-release in March, which sent the stock down over 30% in the pre-market that day, even though the company had already announced its intention to authorize a reverse stock split on its 4Q24 earnings call in February. Due to our liquid asset base and belief in the company's long-term prospects, we were able to buy aggressively in the pre-market and the stock has more than tripled since then. Yet again, this is a classic case of us gaining confidence in an early-stage growth company through our fundamental research, which allowed us to rapidly take advantage of a temporary and unusually attractive entry point due to a trading dislocation in the micro-cap market. BSD Analysis: Outset is trying to reinvent dialysis with its Tablo system — a more flexible, user-friendly platform designed to shift care away from traditional clinics. The thesis is attractive: decentralize dialysis, improve patient quality of life, and cut system-level costs. But medical-device adoption is slow, and reimbursement complexity creates friction. Execution has been uneven, with regulatory setbacks and slower-than-hoped uptake in home dialysis. If Outset can demonstrate consistent safety, reliability, and economic value to providers, the upside is enormous. If not, the burn rate and capital intensity become overwhelming. This is a binary medtech disruptor with real clinical promise but a tough scaling curve.” | BULL | Q2 2025 Jul 1, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
